Main Category: MRSA / Drug Resistance
Also Included In: Infectious Diseases / Bacteria / Viruses;Â Â Urology / Nephrology
Article Date: 02 May 2012 - 1:00 PDT
Patient / Public:
5 (1 votes)
Healthcare Prof:
In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010. In addition, nearly one in four isolates in 2010 were resistant to trimethoprim-sulfamethoxazole (Bactrim®), the second most commonly prescribed drug for this infection. This research was published in the April edition of the journal, Antimicrobial Agents and Chemotherapy.
"Our study is important because it shows that E. coli resistance to two common drugs to treat UTIs rose substantially over the last decade. For patients, this will ultimately translate into more expensive and sometimes more complex antimicrobial treatments. What is more concerning however, is the lack of new antimicrobial drug development which has been declining for decades," said Guillermo Sanchez, a graduate student in the Physician Assistant program at the George Washington University and primary author of the study.
E. coli accounts for 75% to 95% of urinary tract infections (UTIs) and UTIs are among the most common infections in humans, with half of all women experiencing at least one in their lifetime. E. coli antimicrobial resistance is a major factor in determining health outcomes in patients with UTIs. E. coli antimicrobial resistance has been associated with lower likelihood of clinical cure and increased risk of infection recurrence. Additionally, antimicrobial resistance significantly increases patient morbidity, costs of treatment, and rates of hospitalization.
As antimicrobial resistance continues to increase, remaining antimicrobial drug options have a higher likelihood of causing unwanted side effects such as gastrointestinal distress, nausea, and vomiting. Due to a lack of drug development, the paucity of new antimicrobial drugs for common infections like UTIs will continue to worsen in the near future.
"Our study reveals that ciprofloxacin and TMP-SMX are not longer safe for outpatient urinary tract infection (UTI). Our study indicates that safer antimicrobials for outpatient UTI are nitrofurantoin in patients without kidney insufficiency and amoxicillin/clavulanate and third generation cephalosporins for all others", said Jose Bordon, MD Ph.D., AAHIVS, Infectious Disease Specialist at Providence Hospital in Washington, DC.
- Additional
- References
- Citations
MLA
APA
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Five Fold Increase In Antimicrobial Resistance For Common UTI Drug Seen Since 2000'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
Tidak ada komentar:
Posting Komentar